Dishman Carbogen Q1 FY27 loss widens on CDMO deferment

Overview: Q1 FY27 turns loss-making

Dishman Carbogen Amcis reported a sharp deterioration in Q1 FY27 performance, swinging to a consolidated net loss of ₹57.88 crore for the quarter ended June 30, 2026. A year earlier, the company had posted a consolidated net profit of ₹23.41 crore for the same period. Revenue slipped year-on-year, but the bigger impact came from weaker operating profitability and cost pressures. The company attributed the reversal primarily to the deferment of Contract Development and Manufacturing Organisation (CDMO) revenues and higher employee expenses. The results were announced as unaudited financials for the quarter.

Key financial highlights for Q1 FY27

The company reported consolidated income from operations of ₹677.64 crore in Q1 FY27. This was down from ₹708.05 crore in Q1 FY26, reflecting a decline of about 4.3% year-on-year as cited in the disclosures. Operating profitability also weakened, with EBITDA reported at ₹60.10 crore versus ₹140.70 crore in the year-ago quarter, a drop of 57.3%. Basic and diluted EPS for Q1 FY27 stood at (₹3.69) compared with ₹1.49 in Q1 FY26. The quarter also included an exceptional item charge that weighed on reported numbers.

What drove the swing: CDMO revenue deferment

The company flagged deferment of CDMO revenues as a key reason behind the sharp year-on-year swing to losses. CDMO contracts can have milestone-based billing and recognition, so timing shifts can change quarterly revenue and profitability even when underlying demand is intact. In this quarter, the deferment effect coincided with a modest decline in overall revenue, amplifying the impact on operating leverage. The result was a much lower EBITDA base and a net loss at the consolidated level. The disclosures did not quantify the deferred CDMO amount, but it was cited as a primary driver alongside cost increases.

Employee expenses and margin compression

Rising employee expenses were the other major factor cited for the weak quarter. When revenue is down and fixed or semi-fixed costs rise, margins typically compress, and that is visible in the steep EBITDA decline. Q1 FY27 EBITDA of ₹60.10 crore compared with ₹140.70 crore a year ago highlights the extent of the margin pressure. With a weaker operating line, the bottom line moved into a net loss despite revenue remaining above ₹670 crore. The quarter’s profitability was also affected by an exceptional charge related to a fundraise plan that was later dropped.

Standalone performance also turns negative

Alongside the consolidated numbers, standalone operations posted a net loss of ₹23.91 crore for Q1 FY27. This compares with a standalone profit of ₹2.67 crore in Q1 FY26. The standalone decline underlines that the earnings pressure was not limited to one segment of the group’s reporting. The company’s broader business includes CRAMS and the manufacture and supply of marketable molecules such as specialty chemicals, vitamins and chemicals, and disinfectants, with presence in Switzerland, the UK, Europe, China and other regions.

Exceptional item: QIP-related charge after plan dropped

Dishman Carbogen Amcis incurred an exceptional charge of ₹1.69 crore during Q1 FY27. The company linked this cost to a previously proposed Qualified Institutional Placement (QIP) for fundraising. Management later abandoned the QIP, and the related expense was taken as an exceptional item in the quarter. This charge added to the pressure on reported profitability, although the larger drivers remained the CDMO revenue deferment and higher employee expenses.

Capital and liquidity: Board clears ₹75 crore NCD issuance

In a board meeting held on August 12, 2026, the Board of Directors approved the issuance of Non-Convertible Debentures (NCDs) aggregating up to ₹75 crore. The company plans to raise the amount through a private placement of senior, secured, rated, listed, transferable, redeemable, and taxable debentures. The board authorised issuance of up to 7,500 debentures, each with a face value of ₹1,00,000, with the overall issue capped at ₹75 crore across one or more tranches. The NCDs are proposed to be listed on the Wholesale Debt Market Segment of BSE Limited. The disclosure also noted that the NCDs are secured to the extent of a 1.1x security cover.

Dates and investor communication events

The allotment date for the NCDs is scheduled for August 17, 2026, subject to completion of regulatory requirements within the applicable timeline. The maturity date is February 17, 2028, implying an 18-month tenure from allotment. The company also arranged a conference call with investors on Monday, August 17, 2026, from 17:00 hrs to 18:00 hrs IST to discuss Q1 FY27 performance. Separately, a board meeting had been scheduled for Friday, August 14, 2026 to consider and approve the unaudited results, and the trading window closure period was stated as July 1, 2026 to August 16, 2026, with reopening on August 17, 2026.

Market snapshot mentioned alongside results

A market snapshot included with the results commentary referenced Dishman Carbogen Amcis trading around ₹190 to ₹199 per share, with market capitalisation around ₹3,064 crore to ₹3,070 crore in the cited data. One data point also listed a P/E ratio of 30.9, while another note described the P/E as “not meaningful” alongside the results-season context. These figures reflect the market data included in the supplied note and may differ across timestamps and sources.

Summary table: Q1 FY27 vs Q1 FY26

NCD issue terms: key parameters disclosed

Why this quarter matters

The Q1 FY27 outcome highlights how timing-related changes in CDMO revenue recognition can materially affect quarterly profitability, especially when cost lines such as employee expenses rise in parallel. The company’s decision to proceed with an NCD issue up to ₹75 crore also puts focus on funding and liquidity management during a period of weaker earnings. Investors will also track follow-through commentary from the scheduled investor call and any subsequent disclosures on revenue normalisation, cost trends, and capital structure actions within the timelines already announced.